Home » Authors » Brady Huggett

Articles by Brady Huggett

Alteon's ALT-711 Phase II Misses; Confirmatory Trial Being Planned

July 18, 2003

By Brady Huggett

Alteon's ALT-711 Phase II Misses; Confirmatory Trial Being Planned

July 18, 2003

By Brady Huggett

Several Hybridon Presentations Highlight Early Cancer Platform

July 16, 2003

By Brady Huggett

Several Hybridon Presentations Highlight Early Cancer Platform

July 16, 2003

By Brady Huggett

Titan Presents Pivanex NSCLC Data In Early Combination Trial

July 15, 2003

By Brady Huggett

Titan Presents Pivanex NSCLC Data In Early Combination Trial

July 15, 2003

By Brady Huggett

Immunicon Raises $25M, Eyes Device Revenue Inflow In 2004

July 11, 2003

By Brady Huggett

Immunicon Raises $25M, Eyes Device Revenue Inflow In 2004

July 11, 2003

By Brady Huggett

Genentech's Avastin Rights Outside U.S. Go To Roche

July 9, 2003

By Brady Huggett

Genentech's Avastin Rights Outside U.S. Go To Roche

July 9, 2003

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...